SMT202000369T1 - Trattamento di disturbi autoimmuni con anticorpi anti-cd154 - Google Patents
Trattamento di disturbi autoimmuni con anticorpi anti-cd154Info
- Publication number
- SMT202000369T1 SMT202000369T1 SM20200369T SMT202000369T SMT202000369T1 SM T202000369 T1 SMT202000369 T1 SM T202000369T1 SM 20200369 T SM20200369 T SM 20200369T SM T202000369 T SMT202000369 T SM T202000369T SM T202000369 T1 SMT202000369 T1 SM T202000369T1
- Authority
- SM
- San Marino
- Prior art keywords
- antibodies
- treatment
- autoimmune disorders
- autoimmune
- disorders
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1501613.2A GB201501613D0 (en) | 2015-01-30 | 2015-01-30 | Treatment of autoimmune disorders with CD154 antibodies |
| EP15719675.9A EP3250600B1 (en) | 2015-01-30 | 2015-04-27 | Treatment of autoimmune disorders with cd154 antibodies |
| PCT/EP2015/059095 WO2016119909A1 (en) | 2015-01-30 | 2015-04-27 | Treatment of autoimmune disorders with cd154 antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SMT202000369T1 true SMT202000369T1 (it) | 2020-09-10 |
Family
ID=52705552
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SM20200369T SMT202000369T1 (it) | 2015-01-30 | 2015-04-27 | Trattamento di disturbi autoimmuni con anticorpi anti-cd154 |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US20180022812A1 (it) |
| EP (2) | EP3744735A1 (it) |
| KR (1) | KR102543877B1 (it) |
| CN (1) | CN107206075A (it) |
| AU (2) | AU2015379642B2 (it) |
| CA (1) | CA2975336C (it) |
| CY (1) | CY1123116T1 (it) |
| DK (1) | DK3250600T3 (it) |
| ES (1) | ES2802982T3 (it) |
| GB (1) | GB201501613D0 (it) |
| HR (1) | HRP20201013T1 (it) |
| HU (1) | HUE050024T2 (it) |
| LT (1) | LT3250600T (it) |
| PL (1) | PL3250600T3 (it) |
| PT (1) | PT3250600T (it) |
| RS (1) | RS60575B1 (it) |
| RU (1) | RU2695443C2 (it) |
| SI (1) | SI3250600T1 (it) |
| SM (1) | SMT202000369T1 (it) |
| WO (1) | WO2016119909A1 (it) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012125569A2 (en) | 2011-03-11 | 2012-09-20 | Beth Israel Deaconess Medical Center, Inc. | Anti-cd40 antibodies and uses thereof |
| HUE056769T2 (hu) | 2015-09-04 | 2022-03-28 | Primatope Therapeutics Inc | Humanizált anti-CD40 antitestek és felhasználásuk |
| WO2017148904A1 (en) * | 2016-02-29 | 2017-09-08 | Franz Grus | Predictive markers useful in the treatment of wet age-related macular degeneration |
| EP3558363A1 (en) | 2016-12-21 | 2019-10-30 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| US20210317220A1 (en) * | 2018-09-24 | 2021-10-14 | Janssen Biotech, Inc. | Method of providing safe administration of an anti-cd154 antibody |
| CN114895041A (zh) * | 2021-07-01 | 2022-08-12 | 浙江大学 | 一种检测抗蛋白酶体亚基α1-IgG抗体的试剂盒 |
| US12234294B2 (en) | 2021-11-05 | 2025-02-25 | Kiniksa Pharmaceuticals, Gmbh | Pharmaceutical composition of a humanized anti-CD40 antibody |
| WO2023099607A1 (en) * | 2021-12-01 | 2023-06-08 | UCB Biopharma SRL | Formulations comprising fab-peg |
| WO2024222895A1 (zh) * | 2023-04-28 | 2024-10-31 | 信达生物制药(苏州)有限公司 | 抗cd40l抗体及其在人自身免疫疾病治疗的应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| GB9625640D0 (en) | 1996-12-10 | 1997-01-29 | Celltech Therapeutics Ltd | Biological products |
| AU8867501A (en) * | 2000-09-01 | 2002-03-13 | Biogen Inc | Co-crystal structure of monoclonal antibody 5c8 and cd154, and use thereof in drug design |
| GB0303337D0 (en) | 2003-02-13 | 2003-03-19 | Celltech R&D Ltd | Biological products |
| US7563443B2 (en) | 2004-09-17 | 2009-07-21 | Domantis Limited | Monovalent anti-CD40L antibody polypeptides and compositions thereof |
| ES2713859T3 (es) | 2007-03-22 | 2019-05-24 | Biogen Ma Inc | Proteínas de unión, incluyendo anticuerpos, derivados de anticuerpo y fragmentos de anticuerpo, que se unen específicamente a CD154 y usos de los mismos |
| US8435514B2 (en) * | 2008-12-05 | 2013-05-07 | Als Therapy Development Institute | Method for the treatment of neurodegenerative diseases |
| AR083847A1 (es) * | 2010-11-15 | 2013-03-27 | Novartis Ag | Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40 |
| JP6211513B2 (ja) | 2011-04-26 | 2017-10-11 | ジェネンテック， インコーポレイテッド | 自己免疫疾患の治療のための組成物及び方法 |
-
2015
- 2015-01-30 GB GBGB1501613.2A patent/GB201501613D0/en not_active Ceased
- 2015-04-27 RS RS20200831A patent/RS60575B1/sr unknown
- 2015-04-27 EP EP20172402.8A patent/EP3744735A1/en active Pending
- 2015-04-27 RU RU2017130464A patent/RU2695443C2/ru active
- 2015-04-27 CA CA2975336A patent/CA2975336C/en active Active
- 2015-04-27 KR KR1020177024036A patent/KR102543877B1/ko active Active
- 2015-04-27 ES ES15719675T patent/ES2802982T3/es active Active
- 2015-04-27 US US15/547,223 patent/US20180022812A1/en not_active Abandoned
- 2015-04-27 PT PT157196759T patent/PT3250600T/pt unknown
- 2015-04-27 EP EP15719675.9A patent/EP3250600B1/en active Active
- 2015-04-27 DK DK15719675.9T patent/DK3250600T3/da active
- 2015-04-27 SM SM20200369T patent/SMT202000369T1/it unknown
- 2015-04-27 CN CN201580074799.1A patent/CN107206075A/zh active Pending
- 2015-04-27 HU HUE15719675A patent/HUE050024T2/hu unknown
- 2015-04-27 LT LTEP15719675.9T patent/LT3250600T/lt unknown
- 2015-04-27 WO PCT/EP2015/059095 patent/WO2016119909A1/en active Application Filing
- 2015-04-27 PL PL15719675T patent/PL3250600T3/pl unknown
- 2015-04-27 SI SI201531299T patent/SI3250600T1/sl unknown
- 2015-04-27 AU AU2015379642A patent/AU2015379642B2/en active Active
-
2020
- 2020-06-26 HR HRP20201013TT patent/HRP20201013T1/hr unknown
- 2020-07-10 CY CY20201100635T patent/CY1123116T1/el unknown
-
2021
- 2021-06-29 US US17/361,393 patent/US11884737B2/en active Active
-
2022
- 2022-01-19 AU AU2022200347A patent/AU2022200347A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| HUE050024T2 (hu) | 2020-11-30 |
| US11884737B2 (en) | 2024-01-30 |
| GB201501613D0 (en) | 2015-03-18 |
| PT3250600T (pt) | 2020-06-17 |
| HRP20201013T1 (hr) | 2020-10-16 |
| RU2695443C2 (ru) | 2019-07-23 |
| EP3250600A1 (en) | 2017-12-06 |
| RS60575B1 (sr) | 2020-08-31 |
| AU2015379642B2 (en) | 2021-11-04 |
| CN107206075A (zh) | 2017-09-26 |
| PL3250600T3 (pl) | 2020-09-21 |
| KR102543877B1 (ko) | 2023-06-14 |
| AU2015379642A1 (en) | 2017-07-27 |
| SI3250600T1 (sl) | 2020-09-30 |
| EP3744735A1 (en) | 2020-12-02 |
| NZ733454A (en) | 2023-12-22 |
| WO2016119909A1 (en) | 2016-08-04 |
| AU2022200347A1 (en) | 2022-02-17 |
| US20210324095A1 (en) | 2021-10-21 |
| RU2017130464A (ru) | 2019-02-28 |
| CY1123116T1 (el) | 2021-10-29 |
| LT3250600T (lt) | 2020-07-27 |
| DK3250600T3 (da) | 2020-06-08 |
| EP3250600B1 (en) | 2020-05-06 |
| CA2975336C (en) | 2022-10-18 |
| US20180022812A1 (en) | 2018-01-25 |
| CA2975336A1 (en) | 2016-08-04 |
| RU2017130464A3 (it) | 2019-02-28 |
| KR20170106476A (ko) | 2017-09-20 |
| ES2802982T3 (es) | 2021-01-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL285151B1 (en) | Methods for the treatment of fgf21-related disorders | |
| HK1245331A1 (zh) | 基於李斯特菌的疫苗與抗ox40或抗gitr抗體的組合 | |
| IL253803B (en) | A preparation for the treatment of hypothyroidism | |
| HK1258062A1 (zh) | 給予惡拉戈利的方法 | |
| HK1256795A1 (zh) | 可用於治療自身免疫疾病的二吡唑基衍生物 | |
| HUE050024T2 (hu) | Autoimmun rendellenességek kezelése CD154 antitestekkel | |
| HK1231386A1 (zh) | 免疫疾病的治療 | |
| PL3277280T3 (pl) | Izomiosmina do zastosowania w leczeniu chorób autoimmunologicznych | |
| HK1254030A1 (zh) | 治療自身免疫病症和同種免疫病症的方法 | |
| IL269604A (en) | Pentides for the treatment of autoimmune diseases | |
| PL3129483T3 (pl) | Terapia skojarzona do leczenia chorób autoimmunologicznych | |
| SG11201708181RA (en) | Methods for the treatment of inflammatory disorders | |
| EP3145931A4 (en) | Treatment of autoimmune disease | |
| HK1249866A1 (zh) | 用他塞利昔布進行治療的方法 | |
| GB201607388D0 (en) | Treatment of impulsivity-related disorders | |
| HK1255728A1 (zh) | 利用抗il-23a抗體的哮喘治療 | |
| HUE049835T2 (hu) | Szénhidrogének direkt aminálása | |
| GB201514909D0 (en) | Treatment of autoimmune diseases | |
| GB201414023D0 (en) | Treatment of autoimmune diseases | |
| GB201521543D0 (en) | Methods for the treatment of inflammatory disorders | |
| AU2014902194A0 (en) | Treatment of immune disorders | |
| GB201513993D0 (en) | Methods for the treatment of inflammatory disorders | |
| GB201513345D0 (en) | Methods for the treatment of Inflammatory disorders | |
| GB201516140D0 (en) | Treatment of acute inflammatory disorders | |
| GB201509493D0 (en) | Therapeutic antibody |